Shirley Hodgson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shirley Hodgson has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
- Eamonn Richard Maher
Department of Genomic Medicine, University of Cambridge, Cambridge CB2 0QQ, UK
3 shared publications - Andrew D. Beggs
University of Birmingham
2 shared publications Gul Bano
2 shared publicationsIsmail Alrashdi
Department of Medical Genetics, St George's Hospital Medical School, Cranmer Terrace, London, SW17 0RE, UK
2 shared publicationsJ Barwell
Medical and Molecular Genetics Department, Guy's Hospital, London SE1 9RT, UK
2 shared publicationsJohanne Geary
Department of Medical Genetics, St George's University of London, Cranmer Terrace, London SW17 0RE, UK
2 shared publications
Latest Publications
- 3 July 2026
- Published by Taylor & Francis in Medicine, Conflict and Survival
- Vol. 42 (3) , 658-660
Art and citizenship in conflict – British women war artists, 1939–45
The title of this book is enigmatic; it could refer to the fact that it is about women war artists in conflict situations, or to the conflicts experienced by these women between their duties as fem...
- 3 July 2026
- Published by Taylor & Francis in Medicine, Conflict and Survival
- Vol. 42 (3) , 658-660
Art and citizenship in conflict – British women war artists, 1939–45
The title of this book is enigmatic; it could refer to the fact that it is about women war artists in conflict situations, or to the conflicts experienced by these women between their duties as fem...
- 19 September 2025
- Published by Taylor & Francis in Medicine, Conflict and Survival
- Vol. 41 (4) , 557-560
The impossible bomb - the hidden history of British scientists andthe race to create an atomic weapon
- 19 September 2025
- Published by Taylor & Francis in Medicine, Conflict and Survival
- Vol. 41 (4) , 557-560
The impossible bomb - the hidden history of British scientists andthe race to create an atomic weapon
- Open Access
- 21 July 2025
- Published by Wiley in Annals of Human Genetics
- Vol. 89 (5) , 354-365
Inherited Susceptibility to Cancer: Past, Present and Future
Germline pathogenic variants (GPVs, ‘mutations’) causing inherited susceptibility to certain cancers (cancer susceptibility genes, CSGs) broadly belong to one of two main classes—loss of function variants in tumour suppressor genes (TSGs) or gain of function variants in proto‐oncogenes (an over‐simplification). Genomic analyses of tumours identify ‘driver mutations’ promoting tumour growth and somatic variants which contribute to ‘mutation signatures’ which, with histopathology, can be used to subclassify cancers with implications for causality and treatment. The identification of susceptible individuals is important, as they and their relatives may be at elevated risk of tumours, and this can influence optimal cancer treatment. Classically, cancer risk assessment utilises family history, lifestyle/environment factors, and any non‐neoplastic clinical findings, followed by genetic testing of high/moderate penetrance CSGs. In cancer cases not caused by highly penetrant CSGs, multiple variants conferring relatively small risks play a major role. These were discovered by genome‐wide association (GWAS) studies. The utility of polygenic risk scores (PRS) derived from multiple such variants for clinical risk profiling is being assessed. Access to genetic tests is improved by widening eligibility criteria for testing and empowering non‐genetic clinicians to identify CSG GPVs and manage carriers. This will contribute to expanding programmes of screening, prevention and early detection (SPED), with personalised surveillance and prophylactic interventions, and exploit knowledge of the molecular mechanisms of cancer susceptibility to develop novel cancer therapies. In some jurisdictions, population testing is being considered, but GPV penetrance in this setting can be unclear, and the public health implications are complex.
- 21 July 2025
- Published by Wiley in Annals of Human Genetics
- Vol. 89 (5) , 354-365
Open AccessInherited Susceptibility to Cancer: Past, Present and Future
Germline pathogenic variants (GPVs, ‘mutations’) causing inherited susceptibility to certain cancers (cancer susceptibility genes, CSGs) broadly belong to one of two main classes—loss of function variants in tumour suppressor genes (TSGs) or gain of function variants in proto‐oncogenes (an over‐simplification). Genomic analyses of tumours identify ‘driver mutations’ promoting tumour growth and somatic variants which contribute to ‘mutation signatures’ which, with histopathology, can be used to subclassify cancers with implications for causality and treatment. The identification of susceptible individuals is important, as they and their relatives may be at elevated risk of tumours, and this can influence optimal cancer treatment. Classically, cancer risk assessment utilises family history, lifestyle/environment factors, and any non‐neoplastic clinical findings, followed by genetic testing of high/moderate penetrance CSGs. In cancer cases not caused by highly penetrant CSGs, multiple variants conferring relatively small risks play a major role. These were discovered by genome‐wide association (GWAS) studies. The utility of polygenic risk scores (PRS) derived from multiple such variants for clinical risk profiling is being assessed. Access to genetic tests is improved by widening eligibility criteria for testing and empowering non‐genetic clinicians to identify CSG GPVs and manage carriers. This will contribute to expanding programmes of screening, prevention and early detection (SPED), with personalised surveillance and prophylactic interventions, and exploit knowledge of the molecular mechanisms of cancer susceptibility to develop novel cancer therapies. In some jurisdictions, population testing is being considered, but GPV penetrance in this setting can be unclear, and the public health implications are complex.
- Open Access
- 26 June 2025
- Published by BMJ in Journal of Medical Genetics
- Vol. 62 (10) , 628-630
Investigating the use of a patient-facing digital app to support Lynch syndrome carriers in the management of their condition
Lynch syndrome (LS) is an autosomal dominant inherited cancer susceptibility syndrome, resulting from a pathogenic variant affecting DNA mismatch repair genes. Identified carriers require lifelong multisystem care to manage their condition. The aim of this study is to determine whether a patient-facing digital app could be useful for LS carriers in managing their condition. The app includes an evidence-based personal dashboard score showing how up-to-date users are with their LS management. Key findings included that 15% of participants improved their personal dashboard score in 7 weeks of using the app, and 87% would recommend the app to others.
- 26 June 2025
- Published by BMJ in Journal of Medical Genetics
- Vol. 62 (10) , 628-630
Open AccessInvestigating the use of a patient-facing digital app to support Lynch syndrome carriers in the management of their condition
Lynch syndrome (LS) is an autosomal dominant inherited cancer susceptibility syndrome, resulting from a pathogenic variant affecting DNA mismatch repair genes. Identified carriers require lifelong multisystem care to manage their condition. The aim of this study is to determine whether a patient-facing digital app could be useful for LS carriers in managing their condition. The app includes an evidence-based personal dashboard score showing how up-to-date users are with their LS management. Key findings included that 15% of participants improved their personal dashboard score in 7 weeks of using the app, and 87% would recommend the app to others.
- 2 October 2022
- Published by Taylor & Francis in Medicine, Conflict and Survival
- Vol. 38 (4) , 349-351
Battles of conscience: British pacifists and the Second World War
- 2 October 2022
- Published by Taylor & Francis in Medicine, Conflict and Survival
- Vol. 38 (4) , 349-351
Battles of conscience: British pacifists and the Second World War
- Open Access
- 21 March 2022
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 31 (16) , 2728-2737
Elongin C (ELOC/TCEB1)-associated von Hippel–Lindau disease
Around 95% of patients with clinical features that meet the diagnostic criteria for von Hippel–Lindau disease (VHL) have a detectable inactivating germline variant in VHL. The VHL protein (pVHL) functions as part of the E3 ubiquitin ligase complex comprising pVHL, elongin C, elongin B, cullin 2 and ring box 1 (VCB-CR complex), which plays a key role in oxygen sensing and degradation of hypoxia-inducible factors. To date, only variants in VHL have been shown to cause VHL disease. We undertook trio analysis by whole-exome sequencing in a proband with VHL disease but without a detectable VHL mutation. Molecular studies were also performed on paired DNA extracted from the proband’s kidney tumour and blood and bioinformatics analysis of sporadic renal cell carcinoma (RCC) dataset was undertaken. A de novo pathogenic variant in ELOC NM_005648.4(ELOC):c.236A>G (p.Tyr79Cys) gene was identified in the proband. ELOC encodes elongin C, a key component [C] of the VCB-CR complex. The p.Tyr79Cys substitution is a mutational hotspot in sporadic VHL-competent RCC and has previously been shown to mimic the effects of pVHL deficiency on hypoxic signalling. Analysis of an RCC from the proband showed similar findings to that in somatically ELOC-mutated RCC (expression of hypoxia-responsive proteins, no somatic VHL variants and chromosome 8 loss). These findings are consistent with pathogenic ELOC variants being a novel cause for VHL disease and suggest that genetic testing for ELOC variants should be performed in individuals with suspected VHL disease with no detectable VHL variant.
- 21 March 2022
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 31 (16) , 2728-2737
Open AccessElongin C (ELOC/TCEB1)-associated von Hippel–Lindau disease
Around 95% of patients with clinical features that meet the diagnostic criteria for von Hippel–Lindau disease (VHL) have a detectable inactivating germline variant in VHL. The VHL protein (pVHL) functions as part of the E3 ubiquitin ligase complex comprising pVHL, elongin C, elongin B, cullin 2 and ring box 1 (VCB-CR complex), which plays a key role in oxygen sensing and degradation of hypoxia-inducible factors. To date, only variants in VHL have been shown to cause VHL disease. We undertook trio analysis by whole-exome sequencing in a proband with VHL disease but without a detectable VHL mutation. Molecular studies were also performed on paired DNA extracted from the proband’s kidney tumour and blood and bioinformatics analysis of sporadic renal cell carcinoma (RCC) dataset was undertaken. A de novo pathogenic variant in ELOC NM_005648.4(ELOC):c.236A>G (p.Tyr79Cys) gene was identified in the proband. ELOC encodes elongin C, a key component [C] of the VCB-CR complex. The p.Tyr79Cys substitution is a mutational hotspot in sporadic VHL-competent RCC and has previously been shown to mimic the effects of pVHL deficiency on hypoxic signalling. Analysis of an RCC from the proband showed similar findings to that in somatically ELOC-mutated RCC (expression of hypoxia-responsive proteins, no somatic VHL variants and chromosome 8 loss). These findings are consistent with pathogenic ELOC variants being a novel cause for VHL disease and suggest that genetic testing for ELOC variants should be performed in individuals with suspected VHL disease with no detectable VHL variant.
- 2 October 2021
- Published by Taylor & Francis in Medicine, Conflict and Survival
- Vol. 37 (4) , 332-334
Marc Chagall: the artist as peacemaker
This book is one of a series on Peacemakers,1 edited by Ramin Jahanbegloo, which sets out to be a comprehensive collection of the lives of individuals who can be considered to have been peacemakers...
- 2 October 2021
- Published by Taylor & Francis in Medicine, Conflict and Survival
- Vol. 37 (4) , 332-334
Marc Chagall: the artist as peacemaker
This book is one of a series on Peacemakers,1 edited by Ramin Jahanbegloo, which sets out to be a comprehensive collection of the lives of individuals who can be considered to have been peacemakers...
- 12 August 2020
- Published by Taylor & Francis in Medicine, Conflict and Survival
- Vol. 36 (4) , 387-391
Working with refugee families, trauma and exile in family relationships
- 12 August 2020
- Published by Taylor & Francis in Medicine, Conflict and Survival
- Vol. 36 (4) , 387-391
Working with refugee families, trauma and exile in family relationships
- 2 April 2020
- Published by Taylor & Francis in Medicine, Conflict and Survival
- Vol. 36 (2) , 198-200
The health of refugees – public health perspectives from crisis to settlement
- 2 April 2020
- Published by Taylor & Francis in Medicine, Conflict and Survival
- Vol. 36 (2) , 198-200
The health of refugees – public health perspectives from crisis to settlement
- 3 April 2019
- Published by Taylor & Francis in Medicine, Conflict and Survival
- Vol. 35 (2) , 188-191
War doctor
(2019). War doctor. Medicine, Conflict and Survival. Ahead of Print.
- 3 April 2019
- Published by Taylor & Francis in Medicine, Conflict and Survival
- Vol. 35 (2) , 188-191
War doctor
(2019). War doctor. Medicine, Conflict and Survival. Ahead of Print.